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In antineutrophil cytoplasm autoantibody (ANCA)-associated
systemic vasculitis (ASV), autoantibody-induced neutrophil
activation is believed to cause organ damage. In vitro, tumor
necrosis factor a (TNFa) primes neutrophils for ANCA
stimulation and TNFa blockade has been successfully used to
treat ASV. Nonetheless, irreversible organ damage can still
occur, suggesting that other cytokines may circumvent TNFa
blockade. We report that interleukin (IL)-18 deposition, as
assessed by immunoperoxidase staining, is increased in renal
biopsies from ASV patients. Immunofluorescence microscopy
demonstrated that podocytes are the predominant
glomerular IL-18-positive cell type, whereas in the
interstitium, myofibroblasts, distal tubular epithelium, and
infiltrating macrophages stained for IL-18. In vitro, IL-18
primed superoxide production by ANCA-activated
neutrophils comparably to TNFa. IL-18-primed,
ANCA-induced superoxide production was unaffected
by anti-TNFa antibody, which abrogated TNFa priming.
Furthermore, TNFa and IL-18 phosphorylated neutrophil p38
mitogen-activated protein kinase (MAPK), but IL-18-mediated
p38 MAPK phosphorylation was unaffected by anti-TNFa
antibody. The p38 MAPK inhibitor, SB20358, reduced
IL-18-primed, ANCA-induced superoxide production in a
concentration-dependent manner. ANCA-induced superoxide
release was also sensitive to the Leukotriene B4 (LTB4)
inhibitor MK-886. IL-18 priming was not associated with
increased ANCA antigen expression on isolated neutrophils.
We conclude that IL-18 is likely to be important for
neutrophil recruitment and priming in ASV. Therapies
targeting single priming agents may have limited efficacy
in controlling disease.
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Neutrophils are an indispensable component of the immune
system, circulating in an ordinarily quiescent state but rapidly
transmigrating into the foci of infection in order to mediate
efficient microbial killing. Accordingly, neutrophils are
principal mediators of tissue damage when aberrantly
activated, as for example, in antineutrophil cytoplasm
autoantibody (ANCA)-associated systemic vasculitis (ASV).
ASV encompasses a number of related diseases, but evidence
demonstrates that ANCA are pathogenic autoantibodies that
stimulate pro-inflammatory neutrophil functions.1 In vascu-
litis, ANCA are directed against either proteinase 3 (PR3) or
myeloperoxidase (MPO). Recently, pathogenic transfer of
anti-MPO antibodies was reported in a murine model of
vasculitis.2 Additionally, degranulated PR3 and MPO may
themselves exert pathogenic effects upon the endothelium.3
In vitro, neutrophil stimulation by ANCA requires priming,
typically by prior incubation with low concentrations of
tumor necrosis factor a (TNFa).4,5 Attention has mainly
focused upon increased cell surface expression of target
antigens after priming, which may influence the magnitude of
ANCA responsiveness.6–8 However, ANCA also engage Fcg
receptors and b2-integrins, and it is clear that priming can
operate at the level of intracellular signalling pathways that
facilitate activation of the superoxide anion (SO)-generating
nicotinamide adenine dinucleotide phosphate (reduced form)
oxidase complex.9–11 In vivo, the importance of neutrophil
priming in ASV has been inferred from the frequent
association of vasculitis activity with infection, which could
provide the priming signal.12 Circulating neutrophils have
been shown to be primed in active ASV.13,14
Conventionally, remission-induction in ASV has required
global immunosuppression with corticosteroids and cyclo-
phosphamide. Recently, other agents have been assessed in an
attempt to limit drug toxicity and further curtail irreversible
organ damage. In particular, attention has focused on
biological therapies against TNFa that have been used in
other autoimmune diseases. Some reports indicate that anti-
TNFa therapies may be beneficial in ASV, but at least some
patients still incur irrecoverable organ damage, perhaps
suggesting that other cytokines modulate neutrophil activity
under TNFa blockade.15
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Interleukin (IL-18) was originally identified as interferon
g-inducing factor for T-lymphocytes, but was subsequently
recognized as an important component of the innate
immune system with effects upon many cell types.16
Reported effects of IL-18 upon neutrophils include CD11b
upregulation, mobilization of nicotinamide adenine di-
nucleotide phosphate (reduced form) complex components,
p38 mitogen-activated protein kinase (MAPK) phosphoryla-
tion, cytokine and leukotriene synthesis, and priming of
N-formyl-methionyl-leucyl-phenyalanine-induced super-
oxide production.17,18 McInnes and colleagues have identified
important aspects of IL-18 biology in inflammatory arthritis.
IL-18 is present within rheumatoid joints and IL-18-deficient
mice are protected against collagen-induced arthritis.19,20
Furthermore, IL-18-driven neutrophil chemotaxis is TNFa
dependent.21 If this relationship holds true in other settings,
pro-inflammatory effects of IL-18 might still be controlled by
TNFa blockade.
We present evidence that IL-18 is upregulated in renal
biopsies from patients with ASV. Specifically, IL-18-positive
cells within glomeruli were podocytes, whereas IL-18-positive
cells in the interstitium comprised distal tubular epithelial
cells, myofibroblasts, and infiltrating macrophages. In vitro,
IL-18 primes ANCA-induced neutrophil superoxide produc-
tion via phosphorylation of p38 MAPK. Anti-TNFa antibody
abrogates TNFa priming, but does not affect IL-18-primed
superoxide release. Therefore, IL-18 may facilitate ANCA-
induced neutrophil activation under conditions of TNFa
blockade. The leukotriene LTB4 may be implicated in
priming as pretreatment with MK-886 partially inhibited
ANCA-induced superoxide production in neutrophils
primed with either TNFa or IL-18. Priming modulated
surface expression of b2-integrins and L-selectin, but not
ANCA antigens on isolated neutrophils.
RESULTS
IL-18 is expressed in renal tissue from patients with
ANCA-associated vasculitis
Biopsies were used from seven patients with ASV and four
with thin glomerular basement membranes (TGBM), median
age 67 (range 36–80) and 43 (17–54) years, respectively.
Clinical data on ASV patients is shown in Table 1. All ASV
patients were biopsied at initial presentation and had
microscopic haematuria plus proteinuria. For ASV biopsies,
the median number of glomeruli examined per biopsy was
5 (range 4–16). The median percentage of glomeruli affected
by crescents was 75% (range 60–100%). Strongly positive
immunoreactivity for IL-18 was seen in the biopsies from
patients with ASV, whereas biopsies from TGBM patients
were only weakly positive. Immunoperoxidase staining for
IL-18 was seen within the glomeruli, distal tubular epithelial
cells and in the interstitium including in areas of inflam-
matory infiltrate (Figure 1). Glomerular, distal tubular epithelial,
and interstitial staining for IL-18 were all significantly greater
in ASV patient biopsies (Table 2). Proximal tubular epithe-
lium was negative for IL-18 immunoreactivity in all biopsies.
Table 1 | Clinical data for ASV patients
Patient
(sex) Diagnosis
eGFR
(ml/min) CRP (mg/l)
ANCA
specificity+
titre (U/ml) BVAS
1 (M) WG 42 59 PR3 7 16
2 (F) MPA 5 70 MPO4100 26
3 (F) WG 20 53 PR34100 20
4 (F) WG 19 177 PR34100 22
5 (M) MPA 49 56 MPO 74 18
6 (M) MPA 50 127 MPO 39 23
7 (F) MPA 22 11 MPO4100 14
ANCA=antineutrophil cytoplasm autoantibody; ASV=ANCA-associated systemic
vasculitis; BVAS=Birmingham Vasculitis Activity Score; CRP=C reactive protein;
eGFR=estimated glomerular filtration rate (calculated using MDRD formula);
F=female; M=male; MPA=microscopic polyangiitis; MPO=myeloperoxidase;
PR3=proteinase 3; WG=Wegener’s granumolatosis.
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Figure 1 | IL-18 in renal biopsies stained by immunoperoxidase.
IL-18 stained by immunoperoxidase method with haematoxylin
counterstain in biopsies (a–f) from patients with ASV and (g and h)
from patients with TGBM. (a and b) Low-power images of glomeruli
and surrounding tubules, interstitium and inflammatory infiltrate.
(c and d) High-power images of glomeruli from different patients.
(e) Low- and (f) high-power images of distal tubular epithelium with
distal tubular lumen denoted by DT and interstitial cells by arrows.
(g) Low-power image of interstitium from patient with TGBM.
(h) High-power image of glomerulus from patient with TGBM.
Low-power images, original magnification 20, high-power
images, original magnification 60.
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In individual biopsies, glomerular, and interstitial IL-18
staining were predominantly uniform, although not necessa-
rily correlated with one another. Increased density of stain-
ing could be seen in areas of interstitial macrophage
infiltration and within glomerular crescents, although
morphologically normal glomeruli also stained diffusely for
IL-18.
Identity of IL-18-positive cells in renal tissue from patients
with ANCA-associated vasculitis
Dual staining with synaptopodin, smooth muscle actin and
von Willebrand factor demonstrated that IL-18 was present
within podocytes but not activated mesangial or endothelial
cells (Figure 2). IL-18 staining (red) was distributed
throughout the cytoplasm, whereas synaptopodin staining
(green), as expected, localized to the foot process cell
membranes. Consequently, there was little direct overlap of
the two staining patterns (yellow on superimposed images),
but the confocal images clearly suggest that the IL-18-positive
cells are podocytes with synaptopodin staining along cell
membranes surrounding the IL-18-positive cytoplasm
(Figure 2, panels d–f). In contrast, glomeruli dual-stained
for IL-18 (red) and either smooth muscle actin or von
Willebrand factor (both green) show quite separate patterns
of staining (Figure 2, panels g–l).
Interstitial dual staining for IL-18 and CD68 or smooth
muscle actin demonstrated that both interstitial macrophages
and myofibroblasts contained IL-18 (Figure 3). IL-18 in distal
tubular epithelial cells was identified on the basis of the
immunoperoxidase staining and cell morphology.
IL-18 is a potent priming agent for ANCA-induced superoxide
production by neutrophils
In vitro, neutrophil responsiveness to ANCA has been
reported to require TNFa priming.4,5 We assessed IL-18
priming of ANCA-induced SO release and observed
that IL-18 (100 ng/ml for 15 min) primed SO comparably
to optimal concentration TNFa (2 ng/ml for 15 min) (see
Table 3).
Neutrophils treated with IL-18 or TNFa, but not
subsequently stimulated with ANCA, released minimal
superoxide (Table 3, row 1). The time course of superoxide
release was similar in IL-18- and TNFa-primed neutrophils
(not shown). IL-18 was observed to prime neutrophil
responses to both PR3-ANCA and to MPO-ANCA. In these
experiments, PR3-ANCA induced larger responses than
MPO-ANCA, but this was the case when neutrophils were
primed with either TNFa or IL-18. Neither IL-18- nor TNFa-
primed neutrophils responded to immunoglobulin G (IgG)
isolated from healthy donors.
IL-18 priming of the ANCA response was concentration
dependent: 2.9670.44 nmol SO with 0.5ng/ml IL-18 vs
4.7870.41 nmol SO with 100 ng/ml IL-18 (105 neutrophils
primed for 15 min, then stimulated with 200 mg/ml PR3-
ANCA for 45 min, n¼ 4). The magnitude of priming was
inversely related to its duration, such that priming for
430 min induced less ANCA-stimulated SO production
(Figure 4a). In subsequent experiments, we continued to
prime for 15 min with IL-18 to facilitate comparison with
TNFa priming, which is optimal at 15 min. Although the
higher concentrations of TNFa and IL-18 did not produce an
additive priming effect (Table 3, column 4), low concentra-
tions of TNFa (0.1 ng/ml) plus IL-18 (0.1–10 ng/ml) did
reveal an additive effect (Figure 4b). PR3-ANCA-induced SO
production (n¼ 9) was 2.5970.78 nmol after priming with
10 ng/ml IL-18 only and 7.2671.40 nmol with priming by
0.1 ng/ml TNFa plus 10 ng/ml IL-18 (P¼ 0.001 for IL-18 only
vs TNFaþ IL-18). Thus, IL-18 mediates a dose-dependent,
transient priming effect for ANCA-induced superoxide
production.
IL-18 priming is not inhibited by anti-TNFa antibody
TNFa priming of ANCA-induced superoxide production was
inhibited by anti-TNFa antibody in a concentration-depen-
dent manner (Figure 5). TNFa-primed, ANCA-induced SO
release was 8.0471.27 nmol uninhibited vs 2.970.82 nmol
with 1 mg/ml anti-TNFa antibody (n¼ 5, P¼ 0.005). Irrele-
vant human IgG1 did not significantly reduce TNFa priming
(5.871.28 nmol SO, P¼ 0.2). In contrast, anti-TNFa anti-
body did not inhibit IL-18 priming of ANCA-induced
superoxide production. IL-18-primed, ANCA-induced SO
was 6.4670.81 nmol uninhibited, 6.1371.27 nmol with 1 mg/
ml anti-TNFa antibody (P¼ 0.53) and 5.5171.44 nmol with
10 mg/ml anti-TNFa antibody (p¼ 0.81). These data suggest
a direct role for IL-18 in priming superoxide production.
IL-18 priming involves p38 MAPK
TNFa priming of neutrophils has previously been demons-
trated to involve phosphorylation of p38 MAPK and its
inhibition blocks superoxide production induced by ANCA
(after TNFa priming) and other stimuli.22,23 We sought to
confirm IL-18-induced phosphorylation of p38 MAPK and
to determine whether this was TNFa dependent. Both TNFa
and IL-18 induced a rapid and transient phosphorylation
of p38 MAPK in neutrophils (Figure 6). However, only
Table 2 | Scoring of immunoperoxidase staining for IL-18 in
ASV vs TGBM renal biopsies
IL-18 staining score
Median Range
Location ASV TGBM ASV TGBM
Glomerulus 2* 0.75 2–3 0–1
Interstitium 3* 0.5 2–4 0–1
Distal tubular epithelium 1** 0.25 1–2 0–1
ASV=ANCA-associated systemic vasculitis; IL=interleukin; TGBM=thin glomerular
basement membranes.
IL-18 staining by immunoperoxidase in renal biopsies from ASV (n=7) and TGBM
(n=4) disease patients scored in arbitrary units. For each biopsy, separate scores
were determined for the overall intensity of glomerular, interstitial and distal tubular
epithelial IL-18 staining.
*Po0.01 for ASV vs TGBM score.
**P=0.02 for ASV vs TGBM score.
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TNFa-induced phosphorylation of p38 MAPK was inhibited
by anti-TNFa antibody.
We went on to examine the functional significance of p38
MAPK in IL-18 signalling. The p38 MAPK inhibitor,
SB203580, dose dependently reduced ANCA-induced super-
oxide production by IL-18-primed neutrophils (Figure 7). IL-
18-primed, ANCA-induced SO release was 5.070.9 nmol
uninhibited vs 2.0470.77 nmol with 10 mM SB203580
(n¼ 10, Po0.001). SB203580 did not reduce SO release
from unprimed, phorbol 12-myristate 13-acetate-stimulated
cells: 21.875.7 nmol uninhibited vs 25.676.5 nmol with
50 mM SB203580. These findings are consistent with previous
reports that p38 MAPK is important in pre-assembly and
activation of the NADPH oxidase complex, although down-
stream agonists such as phorbol 12-myristate 13-acetate can
circumvent its influence.
Isolated IL-18-treated human neutrophils were recently
shown to produce LTB4 and IL-18-driven chemotaxis of
murine neutrophils was blocked by MK-886, an inhibitor of
LTB4 production.21 We found that MK-886 partially
inhibited superoxide release from both TNFa- and IL-18-
primed neutrophils (Table 4). In contrast, MK-886 did not
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Figure 2 | Identity of IL-18-positive cells in glomeruli of ASV patient renal biopsies. Dual immunohistochemistry was performed for (a, d, g,
j) IL-18 and (b, e) podocyte marker (synaptopodin), (h) endothelial cell marker (von Willebrand factor) or (k) activated mesangial cell marker
(smooth muscle actin). Detail of part of glomerulus from panels a to c shown in panels d–f with nuclear stain (DAPI (40,6-diamidine-20-
phenylindole dihydrochloride) – blue) included to indicate relationship between nucleus, IL-18 and synaptopodin. IL-18 staining is shown in
red, whereas synaptopodin, smooth muscle actin and von Willebrand factor staining are in green. Superimposed images for the corresponding
row are shown in (c, f, i) and (l). Optical magnification 40.
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inhibit superoxide release from unprimed, phorbol 12-
myristate 13-acetate-treated cells.
Effects of IL-18 priming on plasma membrane expression of
PR3 and MPO on isolated neutrophils
Priming of ANCA-mediated neutrophil activation has
been suggested to involve increased expression of the target
antigens upon the plasma membranes of isolated neutrophils.
However, we observed only a very small upregulation of
surface PR3 expression on IL-18-treated neutrophils and a
slightly larger increase after TNFa treatment, although
unprimed, isolated cells already expressed high levels of
PR3 (Table 5 and Figure 8). MPO expression was not
increased by cytokine priming (Table 5 and Figure 8).
Importantly, priming with either cytokine did induce a
significant change in CD18 (increased), CD11b (increased),
and L-selectin (reduced) expression (Table 5 and Figure 9).
DISCUSSION
The identification of key cytokines in inflammatory cascades
that drive autoimmune diseases suggests potential targets for
the therapy. Despite the established role of TNFa priming for
ANCA responses in vitro, recent trials have reached differing
conclusions on the effectiveness of anti-TNFa therapies in
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Figure 3 | Identity of IL-18-positive cells in the interstitium of ASV patient renal biopsies. Dual immunohistochemistry was performed for
( a, d, g, j) IL-18 and (b, e) interstitial myofibroblast marker smooth muscle actin or (h, k) macrophage marker CD68 plus nuclear stain DAPI
(40,6-diamidine-20-phenylindole dihydrochloride) (all panels – blue). IL-18 staining is shown in red, whereas smooth muscle actin and CD68
staining are in green. Superimposed images are shown in (c, f, i) and (l). Panels d–f are magnified details from panels a to c and panels j–l are
magnified details from g to i. Arrowheads in (a–f) indicate smooth muscle actin-positive interstitial cells, whereas arrows in (d–f) indicate nuclei
of tubular epithelial cells. In (g–l), arrowheads indicate macrophages. Optical magnification 40
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ASV.15,24 One potential explanation for continuing organ
damage in patients treated with anti-TNFa therapy is that
other pro-inflammatory cytokines continue to direct leuco-
cyte recruitment and activation.
IL-18 has been implicated in the pathogenesis of
rheumatoid arthritis where it may promote production of
other pro-inflammatory agents, particularly TNFa, direct
Table 3 | ANCA-IgG-induced SO production by neutrophils under various priming conditions
Unprimed n TNFa n IL-18 n TNFa+IL-18 n
No stimulus 0.8370.32 16 1.1370.21 16 1.1270.25 16 1.7970.56 8
PR3-ANCA 2.3570.46 16 7.4570.80 16 7.2971.25* 16 6.6872.00 8
MPO-ANCA 1.4070.54 8 4.8171.05 8 5.1571.80** 8 5.5671.14 8
Normal IgG 1.5470.49 8 1.7670.21 8 1.8270.41 8 1.9670.36 8
ANCA=antineutrophil cytoplasm autoantibody; IgG=immunoglobulin; IL=interleukin; MPO=myeloperoxidase; PR3=proteinase 3; SO=superoxide anion.
*Po0.001 for unprimed vs IL-18-primed neutrophils.
**P=0.03 for unprimed vs IL-18-primed neutrophils.
Neutrophils were treated for 15 min at 371C with medium (‘unprimed’), TNFa (2 ng/ml), IL-18 (100 ng/ml) or TNFa (2 ng/ml) plus IL-18 (100 ng/ml). Results are mean7s.e.m.
superoxide release in nmol/105 cells/45 min of n experiments. Altogether, six healthy neutrophil donors were used, but individual experiments used single donors. PR3-ANCA
results are mean from three different PR3-ANCA fractions (one fraction tested in eight experiments, the other two fractions in four experiments each). MPO-ANCA results are
mean from two different MPO-ANCA fractions (each fraction tested in four experiments). Normal IgG results are the mean of eight experiments conducted using three
fractions from different healthy donors. ANCA fractions were isolated from patients with new presentation, biopsy-proven vasculitic glomerulonephritis and high titre
(X100 m/l) antibodies against the relevant antigen. The clinical diagnosis was WG in one PR3-ANCA-positive patient and MPA in the remaining four patients. Three patients
were dialysis dependent and the other two had less severe renal disease, but suffered pulmonary haemorrhage.
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Figure 4 | IL-18 priming of neutrophil SO release triggered by
PR3-ANCA is time dependent and additive to TNFa priming.
(a) Neutrophils were incubated at 371C with IL-18 (100 ng/ml) for
5–60 min, and then stimulated with PR3-ANCA (200 mg/ml) and SO
release was measured. Results are mean7s.e.m. SO release in nmol/
105 cells/45 min from four separate experiments. (b) Neutrophils were
incubated with medium alone (U), IL-18 (10 ng/ml) only or the
combination of TNFa (0.1 ng/ml) plus IL-18 (0.1–10 ng/ml) for 15 min
at 371C, and then stimulated with PR3-ANCA (200 mg/ml). Results are
mean7s.e.m. SO release in nmol/105 cells/45 min from nine separate
experiments using two PR3-ANCA fractions.
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Figure 5 | IL-18 priming of ANCA-induced SO release is not
inhibited by anti-TNFa antibody. Neutrophils were treated with
HBH alone (‘unprimed’), TNFa (2 ng/ml), or IL-18 (100 ng/ml) for
15 min at 371C. Immediately before the addition of the priming
cytokine, Infliximab (anti-TNFa chimeric IgG1) or control human IgG1
was added at the concentration indicated (0–10 mg/ml). After priming,
cells were stimulated with PR3-ANCA (200 mg/ml). Results are
mean7s.e.m. SO release in nmol/105 cells/45 min from four separate
experiments.
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Figure 6 | Phosphorylation of p38 MAPK by IL-18 is not inhibited
by anti-TNFa antibody. Neutrophils were left unprimed (‘U’) or
treated with 2 ng/ml TNFa (‘TNF’) or 100 ng/ml IL-18 (‘IL-18’) at 371C.
Where indicated (‘þ ’), anti-TNFa antibody (5 mg/ml) was added
immediately before the priming cytokine. Priming continued for ‘5’ or
‘15’ min before reactions were stopped. Five separate experiments
were performed, and representative Western blots for phospho-p38
MAPK and total p38 MAPK (re-probed) are shown together with the
ratio of mean phospho:total p38 for all five experiments, as measured
by densitometry.
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neutrophil chemotaxis, and upregulate endothelial adhesion
molecules.17,20 In animal models of inflammatory arthritis,
IL-18 blockade attenuates disease severity and suggests that
IL-18 is operating ‘upstream’ of TNFa.25
The role of IL-18 in inflammatory renal disease has
received limited attention. Urinary IL-18 is elevated in
acute tubular necrosis and in patients with nephrotic
syndrome.26,27 Calvani et al.28 reported increased glomerular
IL-18 expression in a limited number of renal biopsy
specimens from patients with WHO class IV and V lupus
nephritis. IL-18 was detected in the mesangial matrix and the
authors speculated but did not confirm that infiltrating
monocytes were the predominant source. Tubular IL-18
expression is upregulated in murine models of lupus
nephritis and renal ischaemia.29–31
Intriguingly, we observed the primary source of glome-
rular IL-18 staining in ASV to be podocytes. We did not have
the opportunity to examine podocytes for IL-18 mRNA, but
suspect that podocytes are synthesizing IL-18 in ASV as they
synthesize other cytokines in glomerular disease, specifically
IL-1a, IL-1b, and IL-8.32–34
In ASV, we have previously reported intra-glomerular IL-8
production by both infiltrating leucocytes and intrinsic
glomerular cells.35 By comparison, the glomerular IL-18
staining described here was more diffuse, present within both
crescents and morphologically normal areas of glomeruli. IL-
18 staining within crescents may have originated from
glomerular epithelial cells, although we were not able to
firmly establish this using the available tissue. The role of
infiltrating leucocytes in glomerular IL-18 staining also
requires further investigation as very few intra-glomerular
leucocytes were detected within the sections examined, in
keeping with previous studies.35,36 Nevertheless, we believe
leucocytes are unlikely to account for widespread glomerular
IL-18 staining. Glomerular endothelial cells and activated
mesangial cells did not stain positively for IL-18. Smooth
muscle actin is only expressed by activated mesangial cells,
but it seems unlikely that non-activated mesangial cells
would be a prominent source of IL-18 staining.
In the interstitium, IL-18 co-localized with markers for
myofibroblasts and infiltrating macrophages. IL-18 synthesis
by rheumatoid synovial fibroblasts has been described while
cultured human renal fibroblasts synthesize IL-1, IL-6, and
IL-8.20,37 IL-18 production by monocytes/macrophages has
also been reported.20,38 Renal tubular epithelial cell staining
for IL-18 is consistent with previous murine studies and with
IL-18 expression by other epithelial cell types.30,31,39
We explored the functional role of IL-18 in ANCA-
mediated neutrophil activation and the interdependence
of IL-18 and TNFa priming. In the report by Canetti et al.,21
IL-18-driven neutrophil chemotaxis was inhibited by anti-
TNFa serum and in TNFa receptor-deficient neutrophils.
However, we found that ANCA-induced superoxide produc-
tion from IL-18-primed neutrophils was not significantly
diminished by anti-TNFa antibody. We cannot exclude the
possibility that IL-18 drives priming for ANCA responses
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Figure 7 | IL-18 priming of ANCA-induced SO release is attenu-
ated by p38 MAPK inhibition. Neutrophils were treated with
SB203580 or vehicle, and then primed with IL-18 (100 ng/ml) for
15 min at 371C. Subsequently, neutrophils were stimulated with
ANCA (200 mg/ml). Results are mean7s.e.m. SO release in nmol/105
cells/45 min from 10 separate experiments using six different ANCA
fractions (four PR3-ANCA and two MPO-ANCA).
Table 4 | Effects of LTB4 inhibition on ANCA-IgG-induced SO
production by primed neutrophils
Neutrophil treatment SO release (nmol/45 min)
Uninhibited, TNFa primed, no stimulus 0.4770.10
Uninhibited, TNFa primed+ANCA 5.7071.60
MK 1.0 mM TNFa primed+ANCA 2.1871.13*
MK 0.1 mM TNFa primed+ANCA 4.1671.4*
MK 0.01mM TNFa primed+ANCA 5.2071.49
Uninhibited, IL-18 primed, no stimulus 0.4770.36
Uninhibited, IL-18 primed+ANCA 5.2371.10
MK 1.0 mM, IL-18 primed+ANCA 3.3871.22**
MK 0.1 mM, IL-18 primed+ANCA 4.0171.19**
MK 0.01mM, IL-18 primed+ANCA 4.4672.19
Uninhibited, unprimed+PMA 13.3872.50
MK 1.0 mM, unprimed+PMA 13.1672.07
ANCA=antineutrophil cytoplasm autoantibody; IgG=immunoglobulin; PMA=phor-
bol 12-myristate 13-acetate; SO=superoxide anion.
*Po0.05 compared to TNFa-primed, uninhibited neutrophils.
**Po0.01 compared to IL-18-primed, uninhibited neutrophils.
Neutrophils were incubated with vehicle (‘uninhibited’) or MK-886, before priming
with TNFa (2 ng/ml), IL-18 (100 ng/ml) or medium alone for 15 min at 371C.
Thereafter, neutrophils were left untreated (‘no stimulus’) or stimulated with PR3-
ANCA (200 mg/ml) or PMA (100 ng/ml). Results are mean7s.e.m. superoxide release
in nmol/105 cells/45 min from eight separate experiments.
Table 5 | Effects of cytokine priming upon neutrophil surface
antigen expression
Unprimed IL-18 TNFa
Surface
antigen MFI Range MFI Range MFI Range
PR3 23.5 3.0–50 27.4 3.0–55.8 43.3 3.4–71.1
MPO 3.7 2.1–4.8 2.8 2.3–4.4 3.1 2.6–4.8
CD18 235 179–279 331* 253–442 400 331–466
CD11b 2017 1370–2187 2813* 2167–3889 3491 3162–4532
L-selectin 132 121–164 25.5** 20.1–87.4 17.8 16.9–19.3
IL=interleukin; MFI=median fluorescence intensity; MPO=myeloperoxidase;
PR3=proteinase 3; TNF=tumor necrosis factor alpha.
*P=0.02 for unprimed vs IL-18-primed neutrophils.
**Po0.01 for unprimed vs IL-18-primed neutrophils.
MFI and ranges for PR3, MPO, CD11b, CD18 and L-selectin expression on isolated
neutrophils analyzed after 15 min incubation at 371C with or without TNFa (2 ng/ml)
or IL-18 (100 ng/ml). For PR3 and MPO expression, 12 experiments were performed
using seven healthy neutrophil donors. For CD11b, CD18 and L-selectin expression,
five experiments were performed using four healthy neutrophil donors.
Kidney International (2006) 69, 605–615 611
P Hewins et al.: IL-18 in ANCA-associated small vessel vasculitis o r i g i n a l a r t i c l e
through the production of TNFa that was inaccessible to
anti-TNF antibody, but we observed a rapid, TNFa-antibody-
resistant response after IL-18 priming using a strategy very
similar to Canetti et al.
Our results support a role for p38 MAPK in IL-18-primed
neutrophils stimulated with ANCA. Diminution of SO
release in neutrophils treated with SB203580 could relate to
inhibition of another kinase, but many lines of enquiry have
confirmed the pivotal role of p38 MAPK in cytokine priming
and SO production. TNFa and IL-18 have both been
reported to recruit p38 MAPK and thereby to induce
phosphorylation of certain nicotinamide adenine dinucleo-
tide phosphate (reduced form) oxidase subunits and
neutrophil granule mobilization.18,23,40,41 The functional
importance of p38 MAPK in renal disease is underscored
by both animal and human studies.42,43
Recent reports on the correlation between PR3 expression
upon isolated neutrophils and PR3-ANCA-induced super-
oxide production have produced differing results.8,44 We
observed a clear priming effect of IL-18 upon both PR3-
ANCA- and MPO-ANCA-mediated SO release, with no
significant alteration in PR3 or MPO expression. We
conclude that alterations in ANCA antigen expression are
not the only mechanism of priming relevant to ANCA-
directed activation, and indeed under the conditions we
examined, modulation of PR3/MPO expression may be
relatively unimportant. We did observe increased expression
of the b2-integrins (CD11b and CD18) after cytokine
priming, which other studies suggest may be important in
ANCA-mediated neutrophil activation.11,45,46 Modulation of
intracellular signalling events by cytokine priming, as
outlined above, may also be important. In vivo, expression
of ANCA antigens on neutrophils sequestered within the
microcirculation is likely to be most important, and the
relationship between antigen expression on isolated neutro-
phils and those in the microcirculation remains to be
determined.
LTB4 is a potent neutrophil chemoattractant and has been
reported to augment ANCA-induced neutrophil responses.47
We observed partial MK-886 sensitivity of ANCA-induced
superoxide release after both TNFa and IL-18 priming.
Further assessment of the role of LTB4 in ANCA-mediated
responses seems warranted as it might represent a potential
therapeutic target.
In conclusion, we report that IL-18 is upregulated in
podocytes, interstitial myofibroblasts, infiltrating interstitial
macrophages, and distal tubular epithelial cells in the kidney
during active ASV. In vitro, IL-18 displays a comparable effect
to TNFa in priming ANCA-induced superoxide release.
Moreover, IL-18 priming of superoxide production is not
modulated by TNFa blockade even though TNFa may
mediate IL-18-stimulated chemotaxis. These observations
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Figure 8 | Effects of cytokine priming on surface PR3 and MPO expression on isolated neutrophils. Neutrophils were analysed by flow
cytometry after 15 min incubation at 371C with or without TNFa (2 ng/ml) or IL-18 (100 ng/ml). Representative histograms show fluorescence
intensity for (a) MPO and (b) PR3, with isotype control antibody (solid line), unprimed (bold line) and after priming with IL-18 (dotted grey line).
Box plots represent median (horizontal line) with quartiles (box) and range (T-bars) of fluorescence intensity of isotype control antibody (open
boxes), (c) MPO and (d) PR3.
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may offer new insights into the pathogenesis of ASV.
Furthermore, we believe that IL-18 might be an important
target in novel therapeutic strategies, but that targeting single
cytokines in ASV may be of limited value.
MATERIALS AND METHODS
Tissue section preparation
Renal biopsy specimens were obtained with appropriate local ethics
approval and informed consent, from patients with active vasculitic
glomerulonephritis and positive ANCA serology. Specimens from
individuals with TGBM were used as controls. In all cases, the
histopathological diagnosis was verified by the clinical pathology
service. Snap-frozen specimens were sectioned 6 mm thick on a
cryostat. Thawed sections were fixed in acetone and allowed to dry.
All incubations took place in a humidity chamber at room
temperature, unless otherwise stated.
IL-18 immunohistochemistry
Sections were rehydrated in 0.15 M NaCl containing 0.05 M Tris (pH
7.6) and 0.1% saponin (TBSS), and sequentially blocked with 0.3%
hydrogen peroxide in methanol (20 min), avidin/biotin (Dako-
cytomation, Ely, Cambridge, UK), and TBSS containing 20%
pooled AþBþ human serum (PHS) plus 20% rabbit serum (RS)
(30 min). Each pair of sections were incubated with either mouse
monoclonal anti-human IL-18 (gift from Professor IB McInnes,
Glasgow University, Glasgow, UK) or with mouse IgG2a control
antibody (Dakocytomation) diluted 1:50 with 2% PHS and 2% RS,
at 41C for 14 h. Sections were then incubated with biotinylated
rabbit anti-mouse antibodies (Dakocytomation) 1:50 in TBSS
containing 2% PHS and 2% RS (1 h), followed by streptavidin–
biotin horseradish peroxidase complex (Dakocytomation). Sections
were washed with TBSS following each incubation step. Finally,
staining was visualized with 3,30 diaminobenzamidine dihydro-
chloride and hydrogen peroxide. The reaction was stopped by
washing in distilled water. Sections were counterstained with
Mayer’s haematoxylin.
Glomerular, distal tubular, proximal tubular, and inter-
stitial IL-18 staining were scored (0–4) by a pathologist. The
specificity of the anti-human IL-18 antibody was confirmed
by Western blotting of recombinant human IL-18 protein (not
shown).
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Figure 9 | Effects of cytokine priming on surface activation marker expression on isolated neutrophils. Neutrophils were analysed by flow
cytometry after 15 min incubation at 371C with or without TNFa (2 ng/ml) or IL-18 (100 ng/ml). Representative histograms show fluorescence
intensity for (a) CD11b , (b) CD18 and (c) L-selectin, with isotype control antibody (solid line), unprimed (bold line) and after priming with IL-18
(dotted grey line). Box plots represent median fluorescence (horizontal line) with quartiles (box) and range (T-bars) for (d) CD11b, (e) CD18 and
(f) L-selectin.
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Immunofluorescence
Sections were rehydrated in 0.15 M NaCl containing 0.05 M Tris (pH
7.6) and 0.2% Triton X-100 (TBST), and then blocked with TBST
containing 10% PHS and 10% RS for 30 min. Pairs of sections were
incubated with either mouse anti-human IL-18 or mouse IgG2a
diluted 1:25 in TBST with 1% PHS and 1% RS for 14 h at 41C,
followed by Alexafluor 568-labelled anti-IgG2a (Molecular Probes,
Invitrogen Ltd, Paisley, UK) 1:100 in TBST for 1 h. After each
incubations, sections were washed with TBST. Sections were next
incubated with cell-specific markers or isotype control antibodies in
TBST for 1 h: anti-CD68 IgG1, anti-von Willebrand factor IgG1
(both Dakocytomation), anti-synaptopodin IgG1 (Progen Biotech-
nik GmBH, Heidelburg, Germany), and anti-smooth muscle
actin–flourescein isothiocyanate (FITC)-conjugated IgG2a (Abcam,
Cambridge, UK). Unlabelled primary antibodies were labelled with
FITC-conjugated F(ab0)2 fragments (Molecular probes).
Slides were washed with TBS, fixed in phosphate-buffered saline
with 4% paraformaldehyde for 20 min and washed again. Sections
were then incubated with the nuclear stain DAPI (40,6-diamidine-20-
phenylindole dihydrochloride) (Molecular probes). Sections were
mounted with slow fade (Molecular Probes) and examined by
scanning confocal microscopy.
Neutrophil isolation
Peripheral blood neutrophils were isolated from healthy volunteers
as previously described using Percoll discontinuous density-gradient
centrifugation.5 Neutrophils were resuspended in Hank’s balanced
salt solution (Sigma-Aldrich, Poole, Dorset, UK) buffered with
10 mM HEPES (HBH). Where necessary, neutrophils were incubated
with SB20358 (Calbiochem, EMD Biosciences, San Diego, CA) or
MK-886 (Calbiochem) for 30 or 20 min, respectively. In these
experiments, control neutrophil suspensions were treated with an
equal concentration (1:1000) of vehicle (dimethyl sulphoxide for
SB20358 and ethanol for MK-886). Individual experiments used
neutrophils from a single donor.
Flow cytometry analysis of isolated neutrophils
Isolated neutrophils from healthy donors were resuspended in HBH
(2 106/ml). Fifty microlitres aliquots were incubated with HBH
alone, IL-18 100 ng/ml, or TNF-a 2 ng/ml for 15 min at 371C. For
surface PR3 and MPO expression, samples were then immediately
cooled on ice and incubated with mouse IgG1 isotype control, MPO-
7 mouse anti-human MPO (Dakocytomation), or 4A5 mouse anti-
human PR3 (Wieslab, Lund, Sweden) antibodies for 1 h. After
washing in ice-cold phosphate-buffered saline, FITC-conjugated goat
anti-mouse F(ab0)2 antibody fragment was added for 30 min on ice.
FACS lysis solution (BD Pharmingen, Cowley, Oxford, UK) was
added for 10 min before samples were washed with phosphate-
buffered saline and resuspended in 2% paraformaldehyde in
phosphate-buffered saline. For surface activation marker studies,
neutrophils were mixed with FITC- or phycoerythrin-conjugated
mouse IgG1 isotype control, anti-CD18 FITC (all BD Pharmingen),
anti-CD11b phycoerythrin (BD Pharmingen), or anti-L-selectin FITC
(Dakocytomation) before priming. After 15 min priming, samples
were cooled on ice, residual red blood cells were lysed and samples
were fixed. All samples were analysed on BD FACScalibur flow
cytometer and 10 000 gated events were collected for each sample.
ANCA IgG isolation
IgG was isolated from stored sera of patients with active ASV by
protein G affinity chromatography as described previously.5 All
patients had active Wegener’s granulomatosis or microscopic
polyangiitis based on clinical and serological assessments. Control
IgG was isolated from healthy volunteers. IgG were used at 200mg/
ml based upon the results of previous dose–response experiments.5
ANCA were not affinity purified from total IgG, but ANCA-positive
IgG fractions are referred to as PR3-ANCA and MPO-ANCA
fractions from hereon.
SO release assay
SO release was measured by ferrous cytochrome c reduction as
described previously.5 Neutrophils (2 106/ml) in HBH were first
treated with 5 mg/ml cytochalasin B for 5 min, and then primed at
371C with 2 ng/ml TNFa (NISBC, Potters Bar, UK) or p100 ng/ml
IL-18 (MBL, Nagoya, Japan) for 15 min (unless otherwise stated).
Where necessary, chimeric anti-TNFa antibody (Infliximab, Remi-
cades, Schering-Plough, Welwyn Garden City, UK) or control
human IgG1 (Binding Site, Birmingham, UK) was added to the
neutrophil suspension immediately before priming and also to the
cytochrome c assay.
Western blotting
Neutrophils (1 107/ml) in HBH were primed at 371C with 2 ng/ml
TNFa or 100 ng/ml IL-18. Aliquots (1 ml) were pelleted and boiled
in 2 Laemmli sample buffer. Proteins were separated by 12% SDS-
PAGE and transferred to polyvinylidene difluoride membranes.
Western blotting was performed using antibodies specific for
phosphorylated p38 MAPK (Cell Signaling Technology, Beverly,
MA). Blots were re-probed with antibodies against total p38 MAPK
(Cell Signaling Technology). Primary antibody incubations were
performed overnight at 41C. Horse radish peroxidase-conjugated
secondary antibody was added at room temperature for 1 h.
Densitometry was performed and the ratio of mean phosphorylated
to total p38 MAPK was determined.
Data analysis
Mann–Witney U-test was used for statistical analysis.
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